Диссертация (1141186), страница 25
Текст из файла (страница 25)
// Am J Med. – 1987. – v.83. – p.726-730.54. Brouet J.C., Clouvel J.P.. Danon F. et al. Biologie and clinical significance of cryoglobulins.// Am. Med. – 1974. – v.57. – p.775-788.55. Cacoub P., Lidove O., Maisonobe T., Duhaut P. Interferon-alpha and ribavirin treatment in patients withhepatitis C virus-related systemic vasculitis. // Arthritis Rheum.- 2002.- v.46. – p.3317-3343.56. Cacoub P., Saadoun D., Limal N. et al. PEGylated interferon alfa 2b and ribavirin treatment in patientswith hepatititis C virus-related systemic vasculitis.
// Arthritis Rheum. - 2005. - v.52. – p.911-915.57. Cacoub P., Delluc A., Saadoun D. et al. Anti-CD20 monoclonal antibody (rituximab) treatment forcryoglobulinemic vasculitis: where do we stand? // Ann Rheum Dis. – 2008. – v.67. – p.283-28758. Cacoub P., Gragnani L. Extrahepatic manifestations of chronic hepatitis C virus infection.// Dig LiverDis.- 2014.- v.46.- p.165-173.59. Cacoub P., Terrier B., Saadoun D. Hepatitis C virus-induced vasculitis: therapeutic options.
// Ann.Rheum.Dis. – 2014. – v.73. – p.24-3060. Calleja J.L., Albillos A., Moreno-Otero R. et al. Sustained response to interferon-alfa or to interferonalfa plus ribavirin in hepatitis C virus associated symptomatic mixed cryoglobulinemia. // AlimentPharmacol Ther. - 1999. - v.13. – p.1179-1186.61. Carreño V., Bartolomé J., Castillo I. New perspectives in occult hepatitis C virus infection. // World JGastroenterol. – 2012. – v.18. – p.2887- 2981.14462. Casato M., Agnello V., Pucillo L.P. et al.
Predictors of long-term response to high-dose interferontherapy in type II mixed cryoglobulinemia associated with hepatitis C virus. // Blood. - 1997. – v.90. –p.3865-3873.63. Casato M., Lilli D., Donato G. et al. Occult hepatitis C virus infection in type II mixed cryoglobulinemia.// J Viral Hepat. – 2003. –v.10.
p.455-49964. Chiche L., Bataille S., Kaplanski G., Jourde N. The place of immunotherapy in the management ofHCV-induced vasculitis: an update. // Clin Dev Immunol.- 2012.- 315167.65. Cid M.C., Hernández-Rodríguez J., Robert J., del Río A.Interferon-alpha may exacerbatecryoblobulinemia-related ischemic manifestations: an adverse effect potentially related to its antiangiogenic activity. // Arthritis Rheum.- 1999.- v.42. – p.1051-1056..66. Cornella S.L., Stine J.G., Kelly V.
et al. Persistence of mixed cryoglobulinemia despite cure of hepatitisC with new oral antiviral therapy including direct-acting antiviral sofosbuvir: a case series. // PostgradMed. – 2015. – v. 7. – p. 1-567. Cresta P., Mussel L., Cacoub P et al. Response to interferon alpha treatment and disappearance ofcryoglobulinemia in patients infected by hepatitis C virus. Gut. -1999.- v.45. – p. 122-12868. Dal Maso L., Franceschi S. Hepatitis C virus and risk of lymphoma and other lymphoid neoplasms: ameta-analysis of epidemiologic studies. // Cancer Epidemiol Biomarkers Prev.- 2006.- v.15.
– p.20782163.69. D’Amico G. Renal involvement in hepatitis C infection: Cryoglobulinemic glomerulonephritis inducedby hepatitis C virus. // Kidney Int.- 1998. – v.54. – p.650-67170. Dammacco F., Sansonoo D. Natural interferon–alpha versus its combination with 6-methyl-prednisolonin the therapy of type 2 mixed cryolobulinemia: a long-term, randomized, controlled stady. // Blood.
1994. – v.84. – p.3336-3379.71. Dammacco F., Tucci F.A., Lauletta G., Gatti P. Pegylated interferon-alpha, ribavirin, and rituximabcombined therapy of hepatitis C virus-related mixed cryoglobulinemia: a long-term study. // Blood.2010.- v.116. – p.343-396.72. Dammaco F., Sansonno D. Therapy for hepatitis C virus-related cryoglobulinemic vasculitis. // NewEng. J.Med. – 2013.
– v.369. – p. 1035-104573. Damoiseaux S. The diagnosis and classification of cryoglobulinemic syndrome. // Autoimmun Rev. 2014. – v.13. – p.359-36274. Della Rossa A., Tavoni A., D'Ascanio A. et al. Mortality rate and outcome factors in mixedcryoglobulinemia: the impact of hepatitis C virus. // Scand J Rheumatol.
– 2010. – v.39. – p.167-170.75. De Sanjose at al. Hepatitis C and non-Hodgkin lymphoma among 4784 cases and 6269 controls fromthe International Lymphoma Epidemiology Consortium. // Clin Gastroenterol Hepatol.- 2008.- v.6. –p.451-459.76. De Vita S., Quartuccio L., Fabris M. Hepatitis C virus infection, mixed cryoglobulinemia and BLySupregulation: targeting the infectious trigger, the autoimmune response, or both? // Autoimmun Rev.2008.- v.8.
– p.95-104.77. De Vita S. Treatment of mixed cryoglobulinemia: a rheumatology perspective. // Clin Exp Rheumatol. –2011. – v.29(Suppl 64). – p.99-103.78. De Vita S, Soldano F, Isola M et al. Preliminary classification criteria for cryoglobulinemic vasculitis.//Ann Rheum Dis. -2011.- v.70. – p. 1183-119079. De Vita S., Quartuccio L., Isola M., Mazzaro C. A randomized controlled trial of rituximab for thetreatment of severe cryoglobulinemic vasculitis. // Arthritis Rheum.
– 2012. – v.64. – p.843-896.80. Durand T., Di Liberto G., Colman A. et al. Occult infection of peripheral B cells by hepatitis C variantswhich have low translational efficiency in cultured hepatocytes. // Gut. – 2010. – v.59. – p.934-942.81. Engels EA, Chatterjee N, Cerhan JR et al. Hepatitis C virus infection and non-Hodgkin lymphoma:results of the NCI-SEER multi-center case-control study. Int J Cancer 2004; 111: 76-8082.
Ezzat W.M., Raslan H.M., Aly A.A. Anti-cyclic citrullinated peptide antibodies as a discriminatingmarker between rheumatoid arthritis and chronic hepatitis C-related polyarthropathy. // Rheumatol Int. 2011. – v.31. – p.65-74.83. Fabris M., Quartuccio L., Sacco S. et al. B-lymphocyte stimulator (BLys) up-regulation in mixedcryoglobulinemia syndrome and hepatitis-C virus infection. Rheumatology. – 2007. – v.46.
– p.37-43.14584. Fabrizi F., Fogazzi G.B. Antiviral therapy for HCV-associated cryoglobulinemic glomerulonephritis:case report and review of the literature. // Kidney Blood Press Res. – 2012. – v.35. – p.687-780.85. Fabrizi F., Plaisier E., Saadoun D. Hepatitis C virus infection, mixed cryoglobulinemia, and kidneydisease. // Am J Kidney Dis. – 2013. – v.61. – p.623-660.86. Fabrizi F., Dixit V., Messa P. et al. Interferon mono-therapy for symptomatic HCV-associated mixedcryoglobulinemia: meta-analysis of clinical studies.// Acta Gastroenterol Belg.
– 2013. –v.76. – p.36337187. Ferri C., Greco F., Longombardo G., Palla P., et al. Association between hepatitis C virus and mixedcryoglobulinemia. // Clin Exp Rheumatol. – 1991. - v.9. – p.621-625.88. Ferri C., Marzo E., Longombardo G. et al. Interferon alpha-2b in mixed cryoglobulinemia patients: acrossover- controlled trial. // Blood.- 1993.- v.81.- p.1132-113689.
Ferri C., Zignego A.L., Pileri S.A. Cryoglobulins (review). // J Clin Pathol.- 2002.- v.55. – p.4-13.90. Ferri C., Sebastiani M, Giuggioli D., et al. Mixed cryoglobulinemia: demographic, clinical and serologicfeatures and survival in 231 patients. // Semin. Arthritis Rheumatism. – 2004.- v.33.
–– p.366-374.91. Ferri C., Mascia M.T. Cryoglobulinemic vasculitis. // Curr Opin. Rheumatology. – 2006. – v.18. – p.54 –63.92. Ferri C., Antonelli A. HCV-related autoimmune and neoplastic disorders: the HCV syndrome.//Digestive and Liver Disease.
– 2007. - v.18. - p.13-21.93. Ferri C. Mixed cryoglobulinemia. // Orphanet J Rare Dis. – 2008. - v.16. – p.3-25.94. Ferri C., Cacoub P., Mazzaro C. Treatment with rituximab in patients with mixed cryoglobulinemiasyndrome: results of multicenter cohort study and review of the literature. // Autoimmun Rev. – 2011. –v.11. – p.48-55.95. Ferri C., Sebastiani M., Antonelli A. Current treatment of hepatitis C-associated rheumatic diseases. //Arthritis Res Ther.
– 2012. - v.14. – p.215-225.96. Forghieri F., Luppi M. Pathogenetic Mechanisms of Hepatitis C Virus-Induced B-CellLymphomagenesis. // Clin Dev Immunol. – 2012. - 2012: 807351.97. Friedman G., Mehta S., Sherker A.H. Fatal exacerbation of hepatitis C-related cryoglobulinemia withinterferon-alpha therapy. // Dig Dis Sci. – 1999.
- v.44. – p.1364-1369.98. Giannini C., Petrarca A., Monti M et al. Association between persistent lymphatic infection by hepatitisC virus after antiviral treatment and mixed cryoglobulinemia. // Blood. – 2008. – v.111. – p. 2943-2945.99. Giordano TP, Henderson L, Langren O et al. Risk of non-Hodgkin lymphoma and lymphoproliferativeprecursor diseases in US veterans with hepatitis C virus. JAMA 2007; 297: 2010-2017100.Gisbert J.P., García-Buey L. Prevalence of hepatitis C virus infection in B-cell non-Hodgkin'slymphoma: systematic review and meta-analysis. // Gastroenterology.
- 2003. - v.125. – p.1723-1755.101. Gorevic P.D., Kassab H.J.. Levo Y. et al. Mixed cryoglobulinemia: clinical aspects and long term follow-up of 40 patients. // Am. J. Med.- 1980. –v.69. – p.287-308.102. Gordon A.C., Edgar J.D., Finch R.G. Acute exacerbation of vasculitis during interferon-alpha therapyfor hepatitis C-associated cryoglobulinaemia.
// J Infect. - 1998. – v.36. – p.229-259.103. Granini L, Fognani E., Piluso A., Zignego A.L. Hepatitis C virus-related mixed cryoglobulinemia: isgenetics to blame? //World J Gastroenterol.- 2013.- v.19(47): p.8910-8915104. Gragnani L., Fognani E., Piluso A., Zignego A.L. Hepatitis C-associated B-cell non-Hodgkinlymphomas: the emerging role of miRNA-26b. // J Hepatol.- 2013. - v.59. – p.1362-1365.105.
Gragnani L., Fognani E., Piluso A., Boldrini B. Long-term effect of HCV eradication in patients withmixed cryoglobulinemia: a prospective, controlled, open-label, cohort study. // Hepatology. – 2014.p.1–24.106. Gragnani L., Fabbrizzi A., Triboli E., Urraro T., et al. Triple antiviral therapy in hepatitis C virusinfection with or without mixed cryoglobulinaemia: a prospective, controlled pilot study. // Dig LiverDis.- 2014. – v.46. – p.833-840.107. Halfon P., Bourlière M., Ouzan D., Sène D. Occult hepatitis C virus infection revisited withultrasensitive real-time PCR assay.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
